Read More Pharma Industry News Can VGA039 become a once-monthly standard of care for von Willebrand disease? Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care. byPallavi MadhirajuDecember 8, 2025